As MDM2 is a negative regulator of p53 ... BI 907828 is currently under clinical investigation in two ongoing phase I clinical trials in patients with advanced solid tumours: • NCT03449381 ...

an ERK1/2 inhibitor discovered by Astex that has completed a Phase 2 clinical study and ASTX295 an MDM2 antagonist discovered by Astex in collaboration with the Cancer Research UK Drug Discovery ...

Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical ... and ASTX295 an MDM2 antagonist that has undergone a phase 1 trial.

The agreement transforms Mosaic from a research-focused entity into a clinical-stage business. Mosaic intends to develop proprietary combination ... The in-licensed assets include ASTX029 an ERK1/2 ...